

Nagalakshmi Nadiminty, PhD

Address: Assistant Professor, Department of Urology
Dowling Hall, Rm 2172
3000 Arlington Ave, MS 1091
Toledo, OH 43614

Phone: 419-383-3582
Fax: 419-381-3785
Cell Phone: 716-481-6187
Email: nagalakshmi.nadiminty@utoledo.edu

EDUCATION

2001 PhD, Life Sciences, University of Hyderabad, Hyderabad, India

1994 MSc, Applied Microbiology, SPM Visva Vidyalayam, Tirupati, India

1992 BSc, Biology, Andhra University, Visakhapatnam, India

PAST EMPLOYMENT

2014-June, 2017 UC Davis Medical Center, Sacramento, CA,
Associate Research Biologist

2008-2014 UC Davis Medical Center, Sacramento, CA,
Assistant Research Biologist (at merit levels I, II, and IV)

2004-2007 Roswell Park Cancer Institute, Buffalo, NY,
Post-Doctoral Associate

2002-2004 State University of New York at Buffalo, Buffalo, NY,
Post-Doctoral Associate

2001-2002 AMC Cancer Research Center, Denver, CO,
Post-Doctoral Fellow

PUBLICATIONS

Journals

2017 Tummala R, Lou W, Gao AC, **Nadiminty N**. Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells. *Molecular Cancer Therapeutics*, Jul 20 (epub ahead of press)

2017 Liu C, Armstrong CM, Lou W, Lombard AP, Cuchhiara V, Gu X, Yang JC, **Nadiminty N**, Pan CX, Evans CP, Gao AC. Niclosamide and bicalutamide combination treatment overcomes enzalutamide-and bicalutamide-resistant prostate cancer. *Molecular Cancer Therapeutics*, May 12 (epub ahead of press)

2016 Tummala R, **Nadiminty N**, Lou W, Evans CP, Gao AC. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. *Prostate*, 76(5):445-55.

- 2015 **Nadiminty N**, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF- κ B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. *Molecular Cancer Therapeutics*, 14(8): 1884-95.
- 2015 Liu C, Lou W, Zhu Y, Yang JC, **Nadiminty N**, Gaikwad NW, Evans CP, Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. *Cancer Res*, 75(7): 1413-22.
- 2014 Cui Y, **Nadiminty N**, Liu C, Lou W, Schwartz CT, Gao AC. Upregulation of glucose metabolism by NF- κ B2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. *Endocr Relat Cancer*, 21(3): 435-42.
- 2014 Liu C, Lou W, Zhu Y, **Nadiminty N**, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. *Clin Cancer Res*, 20(12): 3198-210.
- 2014 Zhu Y, Liu C, Cui Y, **Nadiminty N**, Lou W, Gao AC. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). *Prostate*, 74(11): 1086-94.
- 2013 Liu C, Zhu Y, Lou W, **Nadiminty N**, Chen X, Zhou Q, Shi XB, Devere White RW, Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. *Prostate*, 73(4): 418-27.
- 2013 **Nadiminty N**, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. NF- κ B2/p52 induces resistance to Enzalutamide in Prostate Cancer: Role of androgen receptor and its variants. *Molecular Cancer Therapeutics*, 12(8): 1629-37.
- 2013 Tummala R, **Nadiminty N**, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. *American Journal of Pathology*, 183(1): 288-95.
- 2013 Zhu Y, Liu C, **Nadiminty N**, Lou W, Tummala R, Evans CP, Gao AC. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. *Molecular Cancer Therapeutics*, 12(9): 1829-36.
- 2013 Zhu Y, Liu C, Tummala R, **Nadiminty N**, Lou W, Gao AC. RhoGDIalpha downregulates androgen receptor signaling in prostate cancer cells. *Prostate*, 73(15): 1614-22.
- 2012 **Nadiminty N**, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation

of Myc expression in prostate cancer cells. *J Biol Chem*, 287(2): 1527-37.

- 2012 **Nadiminty N**, Gao AC. Mechanisms of persistent activation of the androgen receptor in CRPC: Recent advances and Future perspectives. *World J Urology*, 30(3): 287-95.
- 2012 **Nadiminty N**, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen HW, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. *PLoS One*, 7(3): e32832.
- 2011 Sun M, Liu C, **Nadiminty N**, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. *Prostate*, 72(1): 82-9.
- 2011 Zhu Y, Tummala R, Liu C, **Nadiminty N**, Lou W, Evans CP, Zhou Q, Gao AC. RhoGDI α suppresses growth and survival of prostate cancer cells. *Prostate*, 72(4): 392-8.
- 2011 Liu C, **Nadiminty N**, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. *Genes and Cancer*, 2(2): 151-9.
- 2011 Zhong X, Wang Z, Luo W, Tan Q, Xu F, Zhu W, Wang Q, Wang T, Hou M, **Nadiminty N**, Xue X, Chen J, Ma W, Gao AC, Zhou Q. A proteomic approach to elucidate the multiple targets of selenium induced cell growth inhibition in human lung cancer. *Thoracic cancer*, DOI: 10.1111/j.1759-(Epub ahead of print).
- 2010 **Nadiminty N**, Dutt S, Tepper C, Gao AC. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. *Prostate*, 70(3): 276-87.
- 2010 **Nadiminty N**, Lou W, Sun M, Chen J, Yue J, Kung H-J, Evans CP, Zhou Q, and Gao AC. Aberrant activation of the androgen receptor by NF-kB2/p52 in prostate cancer cells. *Cancer Research*, 70(8): 3309-19.
- 2010 Sun M, Lou W, Chun JY, Cho DS, **Nadiminty N**, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. *Genes and Cancer*, 1(3): 283-92.
- 2010 Chun JY, Tummala R, **Nadiminty N**, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. *Genes and Cancer*, 1(8): 868-76.

- 2010 Yang X, You J, Luo W, Yue J, Ma L, Xiao W, Zhu D, Wu Z, Wang D, **Nadiminty N**, Gao AC, Zhou Q. The N-terminal kinase suppressor of Ras complex has a weak nucleoside diphosphate kinase activity. *Thoracic Cancer*, 1(3): 109-115.
- 2009 Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC. Interleukin-6 regulates androgen synthesis in prostate cancer cells. *Clin Cancer Res*, 15(15): 4815-22.
- 2008 Lee SO, Chun JY, **Nadiminty N**, Lou W, Feng S, Gao AC. Interleukin-4 activates androgen receptor through CBP/p300. *Prostate*, 69(2): 126-32.
- 2008 **Nadiminty N**, Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. *Prostate*, 68(16): 1725-33.
- 2008 **Nadiminty N**, Gao AC. Mechanisms of selenium chemoprevention and therapy in prostate cancer. *Mol Nutr Food Res*, 52(11): 1247-60.
- 2008 Hu Y, Sun M, **Nadiminty N**, Lou W, Pinder E, Gao AC. Transcriptional regulation of human RANK ligand gene expression by E2F1. *Biochem Biophys Res Commun*, 370(3): 440-4.
- 2007 Lee SO, Dutt SS, **Nadiminty N**, Pinder E, Liao H, Gao AC. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. *Prostate*, 67(12): 1293-300.
- 2007 **Nadiminty N**, Chun JY, Hu Y, Dutt S, Lin X, Gao AC. LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. *Biochem Biophys Res Commun*, 359(2): 379-84.
- 2007 Lee SO, Chun JY, **Nadiminty N**, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. *Prostate*, 67(7): 764-73.
- 2006 Lee SO, Yeon Chun J, **Nadiminty N**, Trump DL, Ip C, Dong Y, Gao AC. Methylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). *Prostate*, 66(10): 1070-5.
- 2006 **Nadiminty N**, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF- κ B p100 processing involves CBP/p300-mediated acetylation. *Proc Natl Acad Sci U S A*, 103(19): 7264-9.

- 2006 Chun JY, **Nadiminty N**, Lee SO, Onate SA, Lou W, Gao AC. Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. *Mol Cancer Ther*, 5(4): 913-8.
- 2006 **Nadiminty N**, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, Zhang H, Gao AC. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. *Clin Cancer Res*, 12(5): 1420-30.
- 2005 Lee SO, Lou W, **Nadiminty N**, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. *Prostate*, 64(2): 160-7.
- 2005 Lee SO, **Nadiminty N**, Wu XX, Lou W, Dong Y, Ip C, Onate SA, Gao AC. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. *Cancer Res*, 65(8): 3487-92.
- 2004 Ghosh R, **Nadiminty N**, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. *J Biol Chem*, 280(7): 5812-9.
- 2001 **N. Nagalakshmi** and M.N.V. Prasad. Responses of glutathione cycle enzymes and glutathione metabolism to copper stress in *Scenedesmus bijugatus*. *Plant Science*, 160: 291-299.
- 1998 **N. Nagalakshmi** and M.N.V. Prasad. Copper-induced oxidative stress in *Scenedesmus bijugatus*-Protective role of free radical scavengers. *Bull Environ Contam Toxicol*, 61: 623-628.

Book Chapters

- 2014 **Nadiminty N**, Tummala R, Gao AC: MicroRNAs in the Development and Progression of Prostate Cancer, Singh SR and Rameshwer P, (ed), MicroRNAs in Development and in the Progression of Cancer, Springer.
- 2012 **Nadiminty N**, Tummala R, Zhu Y, Gao AC: NF-kappaB2/p52 in prostate cancer, Tindall DJ, (ed), *Prostate Cancer: Biochemistry, Molecular Biology and Genetics*, Springer.
- 2009 **Nadiminty N**, Gao AC: Selenium and Androgen Receptor in Prostate Cancer, Mohler JL, Tindall DJ, (ed), *Androgen Action in Prostate Cancer*, Springer.

GRANTS

Active

- 07/01/2016 - 06/30/2018 1R21CA202404-01A1 (NCI), \$275,000 total direct costs, Principal Investigator, MicroRNAs Modulate Therapy Resistance in Prostate Cancer
- 07/01/2017 - 06/30/2019 1R03 CA198696-01A1 (NCI), \$100,000 total direct costs, Principal Investigator, Alteration of the miR-let-7c:Lin28 ratio as a predictor of therapy resistance in Prostate Cancer

Completed

- 07/01/2011 - 06/30/2015 Department of Defense Prostate Cancer Research Program, PC100502, \$446,204 total direct costs, Principal Investigator, Novel functions of NF-kappaB2/p52 in prostate cancer
- 07/01/2011 - 06/30/2013 UC Davis Academic Federation (Intramural Funding), \$10,000, Principal Investigator, Loss of miR-let-7c as a predictor of castration resistance in prostate cancer
- 01/01/2011 - 12/31/2011 American Cancer Society - Institutional Research Grant, Grant #95-125-07, \$30,000, Principal Investigator, Regulation of the Lin28/miR-let-7c axis by NF-kappaB2/p52 in prostate cancer

HONORS & AWARDS

- 2015 Molecular Cancer Therapeutics 2013 article featured as one of the 5 most cited articles since its publication in "The Best of AACR Journals 2013"
- 2013 Best Poster Award, AUA Annual Meeting 2013, San Diego, CA
- 2011 Best Poster Award, AUA Annual Meeting 2011, Washington, D.C.
- 2009 Academic Federation Travel Award to attend the AUA Annual Meeting 2009 in Chicago
- 2008 Society for Basic Urologic Research (SBUR) Travel Award to attend the SBUR Annual Fall Meeting 2008 in Phoenix
- 1999 Awarded a travel grant from CSIR, India to attend the 5th International Conference on the Biogeochemistry of Trace Elements, Vienna, Austria
- 1997-2001 Senior Research Fellowship from Council for Scientific and Industrial Research (CSIR), India
- 1995-1997 Junior Research Fellowship from CSIR, India
- 1994 Gold medal for standing first in MSc
- 1992 Best Student Award in BSc

CONFERENCE ACTIVITY

Conferences attended

2016	SBUR Annual Meeting, Scottsdale, AZ
2015	AUA Annual Meeting, New Orleans, LA
2014	AUA Annual Meeting, Orlando, FL
2014	SBUR Annual Meeting, Dallas, TX
2013	AACR Annual Meeting, Washington, DC
2013	AUA Annual Meeting, San Diego, CA
2011	AACR 102nd Annual Meeting, Orlando, FL
2011	AUA Annual Meeting, Washington, DC
2010	AACR 101st Annual Meeting, Washington DC
2010	AUA Annual Meeting, San Francisco, CA
2009	Annual Cancer Research Symposium, UC Davis Cancer Center
2009	AUA Annual Meeting, Chicago, IL
2008	Annual Cancer Research Symposium, UC Davis Cancer Center
2008	Annual Meeting, AACR, San Diego, CA
2008	SBUR Annual Fall Meeting, Phoenix, AZ
2007	Annual Meeting, AACR, Los Angeles, CA
2006	97th Annual Meeting, AACR, Washington, DC
2005	96th Annual Meeting, AACR, Anaheim, CA
1999	International Conference on "Life Sciences in the New Millennium", Invited Speaker, University of Hyderabad, Hyderabad, India
1999	5th International Conference on the Biogeochemistry of Trace Elements, Vienna, Austria
1998	National Symposium on Plant Physiology and Plant Biochemistry, University of Hyderabad, Hyderabad, India

Abstracts presented

- 2015 NF-kappaB2/p52:c-Myc:hnRNPA1 regulatory pathway controls expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. *AUA Annual Meeting 2015.*
- 2014 NF-kappaB2/p52 induces resistance to enzalutamide in Prostate Cancer: Role of androgen receptor and its variants. *AUA Annual Meeting 2014.*
- 2014 miR-Let-7c/Lin28 axis regulates the sensitivity of prostate cancer cells to anti-androgens via AR variants. *SBUR Annual Meeting 2014.*
- 2013 NF-kappaB2/p52 induces resistance to enzalutamide possibly by upregulation of AR-V7. *AACR Annual Meeting, 2013.*
- 2013 NF-κB2/p52 induces expression of inflammatory mediators in prostate cancer in vivo. *AACR Annual Meeting 2013.*
- 2013 NF-κB2/p52 induces resistance to enzalutamide possibly by upregulation of AR-V7. *AUA Annual Meeting 2013.*
- 2013 miR-let-7c axis regulates androgen signaling and the growth of prostate cancer cells. *AUA Annual Meeting 2013.*
- 2011 Andrographolide targets AR pathway in castration-resistant prostate cancer. *2011 Annual Meeting, AUA.*
- 2011 Regulation of intracrine androgen synthesis by NF-kappaB2/p52. *2011 Annual Meeting, AUA.*
- 2011 Andrographolide is a novel inhibitor of Interleukin-6 and suppresses prostate tumor growth. *2011 Annual Meeting, AUA.*
- 2011 Lin28/miR-let-7c axis controls the growth and tumorigenicity of prostate cancer cells. *2011 Annual Meeting, AUA.*
- 2011 Andrographolide is a novel inhibitor of interleukin-6 and suppresses prostate tumor growth. *102nd Annual Meeting, AACR.*
- 2011 Regulation of intracrine androgen synthesis by NF-kappaB2/p52. *102nd Annual Meeting, AACR.*
- 2011 Lin28/miR-let-7c axis controls the growth and tumorigenicity of prostate cancer cells. *102nd Annual Meeting, AACR.*
- 2010 Activation of androgen signaling axis by NF-kappaB2/p52. *101st Annual Meeting, AACR, Washington DC.*
- 2010 Osteoblastic differentiation induced by PSA: Role of Wif-1 and TGF-β.

101st Annual Meeting, AACR, Washington, DC.

- 2010 Interleukin-6 and intracrine androgens in prostate cancer cells. *101st Annual Meeting, AACR. Washington, DC.*
- 2010 Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. *2010 Annual Meeting, AUA.*
- 2009 NF-kappaB2/p52 induces castration-resistant growth of LNCaP cells by protection from apoptosis and cell cycle arrest induced by androgen deprivation and aberrant activation of the androgen receptor. *Annual Meeting 2009, AUA.*
- 2009 NF-kappaB2/p52 induces castration-resistant growth of LNCaP cells by protection from apoptosis and cell cycle arrest induced by androgen deprivation and aberrant activation of the androgen receptor. *Annual Cancer Research Symposium, UC Davis Cancer Center.*
- 2008 Activation of NF-kappaB2 p52 promotes androgen independence in LNCaP prostate cancer cells. *99th Annual Meeting, AACR.*
- 2008 NF-kappaB2/p52 induces castration-resistant growth of LNCaP cells by protection from apoptosis and cell cycle arrest induced by androgen deprivation and aberrant activation of the androgen receptor. *2008 Annual Fall Meeting, SBUR.*
- 2008 NF-kappaB2/p52 promotes androgen-independent growth of LNCaP prostate cancer cells. *Annual Cancer Research Symposium, UC Davis Cancer Center.*
- 2007 NF-kappaB2 p52 promotes androgen-independent growth of LNCaP prostate cancer cells. *Late-breaking abstract, Centennial Annual Meeting, AACR.*
- 2007 Role of Wif-1 and TGF β in the osteoblastic differentiation induced by PSA in SaOS-2 cells. *Centennial Annual Meeting, AACR.*
- 2007 Selenium inhibits the expression of osteogenic genes associated with bone remodeling. *98th Annual Meeting, AACR.*
- 2006 Stat3 induction of NF-kappaB2/p100 processing requires CBP/p300 mediated acetylation. *Late-breaking abstract, 97th Annual Meeting, AACR.*
- 2006 Molecular mechanisms of osteoblastic differentiation induced by PSA in SaOS-2 osteosarcoma cells. *97th Annual Meeting, AACR.*
- 2006 Monomethylated selenium inhibits growth of LNCaP prostate cancer xenograft accompanied by a decrease in the expression of androgen

receptor and prostate specific antigen (PSA). *97th Annual Meeting, AACR.*

- 2006 Mechanisms of selenium down regulation of androgen receptor signaling in prostate cancer. *97th Annual Meeting, AACR.*
- 2005 Prostate specific antigen (PSA) modulates genes involved in bone remodeling and induces osteoblastic differentiation of human osteosarcoma cell line SaOS-2. *96th Annual Meeting, AACR.*
- 2005 Selenium disrupts androgen receptor and estrogen receptor signaling in prostate and breast cancer cells. *96th Annual Meeting, AACR.*

MENTORING EXPERIENCE

- 2015 – June, 2017 Post-doctoral advisees 3
- 2014 - 2015 graduate advisees 1; post-doctoral advisees 4
- 2013 - 2014 graduate advisees 1; post-doctoral advisees 3
- 2012 - 2013 graduate advisees 1; post-doctoral advisees 2
- 2011 - 2012 graduate advisees 1; post-doctoral advisees 1
- 2010 - 2011 graduate advisees 2; post-doctoral advisees 2
- 2009 - 2010 graduate advisees 2; mentored an undergraduate student from Carnegie Mellon University, Pittsburg, PA; post-doctoral advisees 2
- 2008 - 2009 graduate advisees 2; post-doctoral advisees 2

SERVICE TO PROFESSION

Editorial and Advisory Boards

- 2010 - Current Reviewer, World Journal of Urology
- 2011 - Current Reviewer, Molecular Cancer Therapeutics
- 2011 - Current Reviewer, BMC Cancer
- 2012 - Current Reviewer, International Journal of Molecular Sciences
- 2012 - Current Reviewer, PLoS One
- 2013 - Current Reviewer, Cancers
- 2013 - Current Reviewer, International Journal of Nanomedicine
- 2013 - Current Reviewer, International Journal of Biochemistry and Cell Biology
- 2013 - Current Reviewer, BioMed Research International
- 2013 - Current Reviewer, Journal of Clinical Medicine
- 2013 - Current Reviewer, Drug Design, Development and Therapy
- 2015 - Current Associate Editor, Journal of Cancer Prevention and Current Research
- 2015 - Current Reviewer, Asian Journal of Andrology
- 2015 - Current Reviewer, Antioxidants
- 2015 - Current Reviewer, Cancer Research

Grant Reviewer

- 2011-Current Grant Reviewer for Research Grants Council of Hong Kong
- 2014-Current Grant Reviewer for Chief Scientist Office of Scotland

Departmental/University Service

Member, Department of Urology Peer Review Committee, UC Davis, 2008-June, 2017

Member, Status of Women at Davis Administrative Advisory Committee, 2014-June, 2017

Memberships in professional organizations

2004 - Current Member - American Association for Cancer Research (AACR)
2009 - Current Member - Society for Basic Urologic Research (SBUR)
2010 - Current Member - American Urological Association (AUA)